Cargando…

Niraparib exhibits a synergistic anti-tumor effect with PD-L1 blockade by inducing an immune response in ovarian cancer

BACKGROUND: Immune checkpoint blockades (ICBs) therapy showed limited efficacy in ovarian cancer management. Increasing evidence indicated that conventional and targeted therapies could affect tumor-associated immune responses and increase the effectiveness of immunotherapy. However, the effects of...

Descripción completa

Detalles Bibliográficos
Autores principales:	Meng, Jinyu, Peng, Jin, Feng, Jie, Maurer, Jochen, Li, Xiao, Li, Yan, Yao, Shu, Chu, Ran, Pan, Xiyu, Li, Junting, Zhang, Ting, Liu, Lu, Zhang, Qing, Yuan, Zeng, Bu, Hualei, Song, Kun, Kong, Beihua
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2021
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8499579/ https://www.ncbi.nlm.nih.gov/pubmed/34620163 http://dx.doi.org/10.1186/s12967-021-03073-0

Ejemplares similares

Niraparib for ovarian cancer
Publicado: (2021)

Rucaparib and Niraparib in Advanced Ovarian Cancer
por: Redelico, Tyler
Publicado: (2019)

Case Report: Niraparib as Maintenance Therapy in A Patient With Ovarian Carcinosarcoma
por: Zhang, Jie Qing, et al.
Publicado: (2021)

Short-term starvation synergistically enhances cytotoxicity of Niraparib via Akt/mTOR signaling pathway in ovarian cancer therapy
por: Zhi, Wang, et al.
Publicado: (2022)

Correction to: Short‑term starvation synergistically enhances cytotoxicity of Niraparib via Akt/mTOR signaling pathway in ovarian cancer therapy
por: Wang, Zhi, et al.
Publicado: (2022)

Niraparib in ovarian cancer: results to date and clinical potential
por: Caruso, Davide, et al.
Publicado: (2017)

A novel combination of niraparib and anlotinib in platinum-resistant ovarian cancer: Efficacy and safety results from the phase II, multi-center ANNIE study
por: Liu, Guochen, et al.
Publicado: (2022)

Overexpression of PRC1 indicates a poor prognosis in ovarian cancer
por: Bu, Hualei, et al.
Publicado: (2020)

Treatment With Niraparib Maintenance Therapy in Patients With Newly Diagnosed Advanced Ovarian Cancer: A Phase 3 Randomized Clinical Trial
por: Li, Ning, et al.
Publicado: (2023)

Safety and management of niraparib monotherapy in ovarian cancer clinical trials
por: Monk, Bradley J, et al.
Publicado: (2023)

Hyperemesis gravidarum induced refeeding syndrome causes blood cell destruction: a case report and literature review
por: Pan, Xiyu, et al.
Publicado: (2021)

How to start niraparib in real-world Asian ovarian cancer patients?
por: Hong, Sook-Hee
Publicado: (2021)

Pharmacological effects of Niraparib and its combination with angiogenic inhibitor in ovarian cancer
por: Liu, Huiwen, et al.
Publicado: (2023)

Cost-effectiveness of maintenance niraparib with an individualized starting dosage in patients with platinum-sensitive recurrent ovarian cancer in China
por: Shi, Yin, et al.
Publicado: (2023)

Niraparib: A Review in First-Line Maintenance Therapy in Advanced Ovarian Cancer
por: Lee, Arnold
Publicado: (2021)

Niraparib and Advanced Ovarian Cancer: A Beacon in the Non-BRCA Mutated Setting
por: Maiorano, Mauro Francesco Pio, et al.
Publicado: (2023)

Real‐world outcomes of niraparib treatment in patients with ovarian cancer: a multicenter non‐interventional study in China
por: Li, Jin, et al.
Publicado: (2023)

Evaluation of the prognostic value of lymphadenectomy for low-grade serous ovarian cancer: A case-control multicenter retrospective study
por: Chen, Zhongshao, et al.
Publicado: (2022)

PD-1 Blockade and OX40 Triggering Synergistically Protects against Tumor Growth in a Murine Model of Ovarian Cancer
por: Guo, Zhiqiang, et al.
Publicado: (2014)

Niraparib activates interferon signaling and potentiates anti-PD-1 antibody efficacy in tumor models
por: Wang, Zebin, et al.
Publicado: (2019)

Rad50 promotes ovarian cancer progression through NF‐κB activation
por: Li, Yinuo, et al.
Publicado: (2021)

Fertility and prognosis assessment between bleomycin/etoposide/cisplatin and paclitaxel/carboplatin chemotherapy regimens in the conservative treatment of malignant ovarian germ cell tumors: a multicenter and retrospective study
por: Chu, Ran, et al.
Publicado: (2022)

Effects of Neoadjuvant Chemotherapy in Ovarian Cancer Patients With Different Germline BRCA1/2 Mutational Status: A Retrospective Cohort Study
por: Fu, Mengdi, et al.
Publicado: (2022)

Coexistence of benign struma ovarii, pseudo-Meigs’ syndrome and elevated serum CA 125: Case report and review of the literature
por: JIN, CHENGJUAN, et al.
Publicado: (2015)

An In-Depth Review of Niraparib in Ovarian Cancer: Mechanism of Action, Clinical Efficacy and Future Directions
por: Akay, Melek, et al.
Publicado: (2021)

Correction to: Niraparib: A Review in First-Line Maintenance Therapy in Advanced Ovarian Cancer
por: Lee, Arnold
Publicado: (2021)

Correction: PD-1 Blockade and OX40 Triggering Synergistically Protects against Tumor Growth in a Murine Model of Ovarian Cancer
por: Guo, Zhiqiang, et al.
Publicado: (2017)

Current Advances in PD-1/PD-L1 Blockade in Recurrent Epithelial Ovarian Cancer
por: Zhang, Yuedi, et al.
Publicado: (2022)

Implication of combined PD-L1/PD-1 blockade with cytokine-induced killer cells as a synergistic immunotherapy for gastrointestinal cancer
por: Dai, Congqi, et al.
Publicado: (2016)

Synergistic efficacy of simultaneous anti-TGF-β/VEGF bispecific antibody and PD-1 blockade in cancer therapy
por: Niu, Mengke, et al.
Publicado: (2023)

The efficacy and safety of niraparib for ovarian cancer: a single-center observational study from China
por: Ni, Jing, et al.
Publicado: (2021)

Safety Profile of Niraparib as Maintenance Therapy for Ovarian Cancer: A Systematic Review and Meta-Analysis
por: Pagkali, Antonia, et al.
Publicado: (2022)

Cost-Effectiveness of Niraparib and Olaparib as Maintenance Therapy for Patients with Platinum-Sensitive Recurrent Ovarian Cancer
por: Zhong, Lixian, et al.
Publicado: (2018)

PD-1/PD-L1 blockades in non-small-cell lung cancer therapy
por: Jing, Wang, et al.
Publicado: (2016)

Pharmacokinetics and safety of niraparib in patients with moderate hepatic impairment
por: Akce, Mehmet, et al.
Publicado: (2021)

Niraparib-induced STAT3 inhibition increases its antitumor effects
por: Zhao, Qianqian, et al.
Publicado: (2022)

Case Report: Niraparib-Related Pulmonary Embolism During the Treatment of BRCA Mutant Advanced Ovarian Cancer
por: Wei, Qiang, et al.
Publicado: (2022)

A phase 1 evaluation of the safety and tolerability of niraparib in combination with everolimus in advanced ovarian and breast cancers
por: Starks, David, et al.
Publicado: (2023)

Efficacy of poly (ADP-ribose) polymerase inhibitors monotherapy and the impact to subsequent platinum-based chemotherapy in breast cancer susceptibility genes1/2-mutated ovarian cancer patients with secondary platinum-sensitive relapse
por: Ma, Yana, et al.
Publicado: (2023)

Clinical features and prognostic factors analysis of intravenous leiomyomatosis
por: Chen, Jingying, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_hfaj4acesg2r2a2ndcaldga0ub